Research News and Research

RSS

Thermo Fisher signs asset purchase agreement with Nephromics for PlGF assay

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights to use PlGF for the diagnosis of pre-eclampsia or eclampsia. Clinical trials have shown that PlGF supports the diagnosis and risk prediction for preeclampsia.

From Thermo Fisher Scientific Inc. 16 May 2012

First study to compare complication rates after RAPN and LPN

Robot-assisted surgery has replaced another minimally invasive operation as the main procedure to treat kidney cancer while sparing part of the diseased organ, and with comparable results, according to a new research study by Henry Ford Hospital urologists.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Exendin-4 drug effectively suppresses craving for food

A drug made from the saliva of the Gila monster lizard is effective in reducing the craving for food. Researchers at the Sahlgrenska Academy, University of Gothenburg, have tested the drug on rats, who after treatment ceased their cravings for both food and chocolate.

16 May 2012

Mass. Eye and Ear announces recipients of 2012 Curing Kids Fund grants

The Mass. Eye and Ear Curing Kids fund has awarded grants for research projects that aim to help the brain locate sound, identify genes that cause congenital blindness, cure deafness through hair cell regeneration, and improve treatment for childhood eye cancer.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

Coromega introduces emulsified form of omega-3s

Premier supplements maker Coromega today announced a delicious new way to help Americans reach healthy omega-3 levels with the launch of Coromega Big Squeeze, an emulsified form of omega-3s delivered in an easy-to-use, family-size pouch with superior absorption to that of traditional fish oil capsules.

16 May 2012

Derma Sciences first quarter net sales increase 6% to $15.3 million

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three months ended March 31, 2012.

15 May 2012

Harvard cardiologist receives Cedars-Sinai’s Corday Prize in Heart Research

Cedars-Sinai Heart Institute is honoring Eugene Braunwald, MD, Distinguished Hersey Professor of Medicine at Harvard Medical School, with The Eliot Corday, MD, International Prize in Heart Research. The Corday Prize has been established to recognize physicians and scientists conducting groundbreaking research that has, or very likely will, change the practice of heart medicine. Braunwald is the inaugural recipient of the annual prize.

15 May 2012

Study demonstrates long-term effectiveness of classroom-based drug prevention program

A new study presented at an international conference in Texas demonstrates the long-term effectiveness of a classroom-based prevention program targeting teen drug use.

15 May 2012

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.

15 May 2012

Researchers find protein that controls neurotransmission: findings may lead to new drugs to treat neurological disorders

Scientists at Weill Cornell Medical College have discovered that the single protein -- alpha 2 delta -- exerts a spigot-like function, controlling the volume of neurotransmitters and other chemicals that flow between the synapses of brain neurons. The study, published online in Nature, shows how brain cells talk to each other through these signals, relaying thoughts, feelings and action, and this powerful molecule plays a crucial role in regulating effective communication.

15 May 2012

Health care system should provide proactive interventions to prevent depression

Major depressive episodes can be prevented, and to help ensure that they are, the health care system should provide routine access to depression-prevention interventions, just as patients receive standard vaccines, according to a new article co-authored by UCSF researcher Ricardo F. Mu-oz, PhD.

15 May 2012

Study finds more than three-fourths of battery-related visits to ED by children

In today's technology-driven world, batteries, especially button batteries, are everywhere. They power countless gadgets and electronic items that we use every day. While they may seem harmless, button batteries can be dangerous if swallowed by children.

15 May 2012

First study to track movement of individuals with dementia until death

A new study from the Regenstrief Institute and Indiana University has found that, at time of death, individuals with dementia are more likely to be living at home than in a nursing home. This contradicts the commonly held view that most individuals with dementia in the United States eventually move to nursing homes and die there.

15 May 2012

Persistent Systems, TGen collaborate on Bio4D software program

Persistent Systems, the leader in outsourced software product development (OPD) services, and the Translational Genomics Research Institute (TGen) today announced that they are developing a high-quality biospecimen management system called Bio4D.

15 May 2012

Significant breakthrough in understanding the cause of bile duct cancer

A team of international scientists has made a significant breakthrough in understanding the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes frequently mutated in bile duct cancers, researchers are paving the way for better understanding of how bile duct cancers develop. Their discovery is published online in Nature Genetics.

15 May 2012

Human embryonic stem cells can be used to grow bone tissue grafts

Dr. Darja Marolt, an Investigator at The New York Stem Cell Foundation (NYSCF) Laboratory, is lead author on a study showing that human embryonic stem cells can be used to grow bone tissue grafts for use in research and potential therapeutic application. Dr. Marolt conducted this research as a post-doctoral NYSCF - Druckenmiller Fellow at Columbia University in the laboratory of Dr. Gordana Vunjak-Novakovic.

15 May 2012

Study identifies biomarkers that can predict recurrence of prostate cancer

Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study has found.

15 May 2012

Paediatric brain tumours preserve specific characteristics of normal cells from which they originate

Paediatric brain tumours preserve specific characteristics of the normal cells from which they originate - a previously unknown circumstance with ramifications for how tumour cells respond to treatment.

15 May 2012